Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropyl Alcohol SCHEMBL9715122 | 0.97 | ALDH1A1 (0.38) | ALDH1A1LMNATSHRMAPK1CYP2C19 | |
| Hydrogen Peroxide SCHEMBL28073128 | 0.90 | TSHR (0.35) | TSHRMMP8 | |
| Methyl Alcohol SCHEMBL375169 | 0.90 | TSHR (0.35) | TSHRMMP8 | |
| SCHEMBL30487170 | 0.89 | — | — | |
| SCHEMBL2686745 | 0.89 | — | — | |
| SCHEMBL11485188 | 0.89 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL2713018 | 0.89 | — | — | |
| SCHEMBL23992 | 0.89 | — | — | |
| Acetone SCHEMBL20597859 | 0.89 | ALDH1A1 (0.38) | ALDH1A1LMNACYP2C19TDP1MMP8 | |
| Hypochlorous Acid SCHEMBL11413271 | 0.87 | TSHR (0.33) | ALDH1A1TSHRCYP2C19MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218616-A1 | Combinations for Treatment of NAFLD/NASH and Related Diseases | PFIZER INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-11254660-B2 | Combinations for treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200071351-A1 | TACCALONOLIDE MICROTUBULE STABILIZERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-03-05 | — | — | US | disclosed |
| US-20200071306-A1 | Combinations For Treatment Of NASH/NAFLD And Related Diseases | PFIZER INC. (US) | 2020-03-05 | — | — | US | disclosed |
| EP-3554509-A1 | TACCALONOLIDE MICROTUBULE STABILIZERS | The Board of Regents of The University of Texas System (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018112391-A1 | TACCALONOLIDE MICROTUBULE STABILIZERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20170313739-A1 | TACCALONOLIDE MICROTUBULE STABILIZERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-11-02 | — | — | US | disclosed |
| US-20160257707-A1 | TACCALONOLIDE MICROTUBULE STABILIZERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-09-08 | — | — | US | disclosed |
| US-9340572-B2 | Taccalonolide microtubule stabilizers | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140357608-A1 | TACCALONOLIDE MICROTUBULE STABILIZERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-12-04 | — | — | US | disclosed |
| EP-2718297-A2 | NEW TACCALONOLIDE MICROTUBULE STABILIZERS | The Board of Regents of The University of Texas System (US) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012170573-A2 | NEW TACCALONOLIDE MICROTUBULE STABILIZERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-12-13 | — | — | WO | disclosed |
| EP-1501819-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-09-15 | — | — | EP | disclosed |
| US-7138426-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050234245-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | disclosed |
| US-20020082289-A1 | Intermediates for pesticidal composition comprising enantiomeric form of fipronil | HUBER SCOT KEVIN (US) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071351-A1 | TACCALONOLIDE MICROTUBULE STABILIZERS | MAP1LC3B, MAP1LC3A, MAP1LC3C | ALDH1A1 3519/4885LMNA 3576/4885TSHR 3779/4885 |
| US-20170313739-A1 | TACCALONOLIDE MICROTUBULE STABILIZERS | MAP4, MAP1LC3B, MAP1LC3A | ALDH1A1 3215/4885LMNA 4265/4885TSHR 3885/4885 |
| US-20140357608-A1 | TACCALONOLIDE MICROTUBULE STABILIZERS | MAP4, MAP1LC3B, MAP1LC3A | ALDH1A1 3215/4885LMNA 4265/4885TSHR 3885/4885 |
| US-11254660-B2 | Combinations for treatment of NASH/NAFLD and related diseases | FABP1, PPARG, GOT2 | ALDH1A1 399/4885LMNA 1752/4885TSHR 1835/4885 |
| US-20230218616-A1 | Combinations for Treatment of NAFLD/NASH and Related Diseases | FABP1, GOT2, CPT1A | ALDH1A1 324/4885LMNA 1060/4885TSHR 2810/4885 |
| US-20050234245-A1 | Estrogen receptor modulators | ESRRB, ESR2, GPER1 | ALDH1A1 2303/4885LMNA 873/4885TSHR 571/4885 |
| US-20160257707-A1 | TACCALONOLIDE MICROTUBULE STABILIZERS | MAP4, MAP1LC3B, MAP1LC3A | ALDH1A1 3215/4885LMNA 4265/4885TSHR 3885/4885 |
| US-20020082289-A1 | Intermediates for pesticidal composition comprising enantiomeric form of fipronil | POR, CYP2E1, FIP1L1 | ALDH1A1 205/4885LMNA 3378/4885TSHR 1915/4885 |
| US-20200071306-A1 | Combinations For Treatment Of NASH/NAFLD And Related Diseases | FABP1, PPARG, GOT2 | ALDH1A1 399/4885LMNA 1752/4885TSHR 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.